Archives

by in
Entry Author Date Location
Disappointments, New Prospects for Rigel Pharmaceuticals 09/10/13 San Francisco
Are Some Degrees Better than Others for Big Pharma Leaders? 09/09/13 Seattle
East Coast Life Sciences Roundup: Syndax, Enteris, Invivo, & More 08/30/13 Boston
Amgen Agrees to Buy Onyx for $125 Per Share, or $10.4B 08/25/13 San Francisco
Hutch’s “Project Violet” Taps Crowd, Seeks $20M for Drug Discovery 08/15/13 Seattle
Buoyed by Partnerships, Bind Therapeutics Floats $80.5M IPO Plan 08/12/13 Boston
Array Biopharma Cuts Staff by 20%, Loses Development Deal with Amgen 08/07/13 Boulder/Denver
The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts 07/22/13 National
Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks 07/15/13 National
Baseball and Biopharma: More Alike Than You Might Realize 07/03/13 Seattle
NGM, Partners Seek Next Diabetes Drug Targets Among GI Tract Hormones 06/25/13 San Francisco
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
CytomX Snags $25M From Pfizer to Make Souped-Up Antibodies 06/06/13 San Francisco
We Owe it to Patients to Provide a Reliable Supply of Medicines 06/04/13 National
Assigning Credit and Blame to Biopharma R&D Chiefs 05/29/13 Seattle
East Coast Life Sciences Roundup: Termeer, Atlas, OSI Pharma & More 05/17/13 Boston
Atlas Leans on Amgen, Novartis to Build New Startups 05/16/13 Boston
Radius Health CEO: Skin Patch Data is the Value Driver 05/13/13 Boston
NW Biotech Education Group Faces Loss of Federal Money, Deep Cuts 05/02/13 Seattle
Bind Therapeutics, AstraZeneca Collaborate on Cancer Drug 04/22/13 Boston
From Assets to Zen: Building Successful Drug Hunting Relationships 04/22/13 San Diego
East Coast Life Sciences Roundup: Optimer, Bind, Pfizer, and More 04/05/13 Boston
Bind Therapeutics Reels Pfizer into Nanomedicine Partnership 04/03/13 Boston
Gilead Sciences Building on HIV, Becoming Cancer Drug Force 04/01/13 National
AstraZeneca Shells Out $240M Upfront For Moderna mRNA Drugs 03/21/13 Boston
Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal 03/18/13 San Francisco
Has The Pendulum Swung Too Far in Favor of Rare Diseases? 03/14/13 Seattle
Some Bold Baseball and Biotech Picks for the 2013 Season 03/11/13 National
East Coast Life Sciences Roundup: Merck, Celgene, PTC, Cerulean 03/08/13 Boston
Roger Perlmutter Returns to Merck, Looks to Biotech Future (Again) 03/07/13 New York
Page 2 of 13 « previous page · next page »